Lancet

ASH 2025: Improved response seen in relapsed follicular lymphoma with chemotherapy-free regimen

December 19, 2025

The phase 3 EPCORE FL-1 trial (NCT05409066) demonstrated that epcoritamab plus lenalidomide-rituximab (R²) significantly outperformed R² alone in patients with relapsed/refractory follicular lymphoma after ≥1 prior line of chemoimmunotherapy. These findings were presented at the recent American Society of Hematology 2025 meeting. At median 14.8-month follow-up, the combination achieved a 95% overall response rate vs. 79% with R² alone (p<0.0001), with estimated 16-month progression-free survival of 85.5% vs. 40.2% (hazard ratio [HR], 0.21; p<0.0001). Cytokine release syndrome was predominantly low-grade (21% grade 1, 5% grade 2) and manageable. Grade ≥3 adverse events occurred more frequently with the triplet regimen (90% vs. 68%).

Source:

Falchi L, et al; EPCORE FL-1 Investigators. (2025, December 7). Lancet. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. https://pubmed.ncbi.nlm.nih.gov/41371238/